Literature DB >> 27184342

Number of metastatic lymph nodes as determinant of outcome after salvage radical prostatectomy for radiation-recurrent prostate cancer.

G Gugliemetti1, R Sukhu2, M A Conca Baenas1, J Meeks1, D D Sjoberg2, J A Eastham3, P T Scardino3, K Touijer4.   

Abstract

BACKGROUND: Presence of lymph node metástasis (LNM) at salvage radical prostatectomy (sRP) is associated with poor outcome. Predictors of outcome in this context remain undetermined. ThE objective was to assess the role of number of positive lymph node on outcome of patients with LNM after sRP and for radio-recurrent prostate cancer.
MATERIAL AND METHODS: We analyzed data from a consecutive cohort of 215 men treated with sRP at a single institution. We used univariate Cox proportional hazard regression models for biochemical recurrence (BCR) and metastatic outcomes, with prostate-specific antigen, Gleason score, extraprostatic extension, seminal vesicle invasion, time between radiation therapy and sRP, and number of positive nodes as predictors.
RESULTS: Of the 47 patients with LNM, 37 developed BCR, 11 developed distant metastasis and 4 died with a median follow-up of 2.3 years for survivors. The risk of metastases increased with higher pre-operative PSA levels (HR 1.19 per 1ng/ml; 95% CI: 1.06-1.34; P=.003). The remaining predictors did not reach conventional levels of significance. However, removal of 3 or more positive lymph nodes demonstrated a positive association, as expected, with metastatic disease (HR 3.44; 95% CI: 0.91-13.05; P=.069) compared to one or 2 positive nodes. Similarly, the presence of extraprostatic extension, seminal vesicle invasion and Gleason grade greater than 7 also demonstrated a positive association with higher risk of metástasis, with hazard ratios of 3.97 (95% CI: 0.50, 31.4; P=.2), 3.72 (95% CI: 0.80-17.26; P=.1), and 1.45 (95% CI: 0.44-4.76; P=.5), respectively.
CONCLUSIONS: In patients with LNM after sRP for radio-recurrent prostate cancer, the risk of distant metástasis is likely to be influenced by the number of positive nodes (3 or more), high preoperative PSA, Gleason grade and advanced pathologic stage. These results are consistent with the findings of number of nodes (1 to 2 vs. 3 or more nodes positive) as a prognostic indicator after primary radical prostatectomy and strengthen the plea for a revision of the nodal staging for prostate cancer.
Copyright © 2016 AEU. Publicado por Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Cáncer de próstata; Disección de ganglios linfáticos; Estadificación; Lymph node dissection; Lymph node metástasis; Metástasis de ganglios linfáticos; Prognosis; Pronóstico; Prostate cancer; Radiation therapy; Radioterapia; Salvage therapy; Staging; Terapia de rescate

Mesh:

Year:  2016        PMID: 27184342      PMCID: PMC5553201          DOI: 10.1016/j.acuro.2016.02.008

Source DB:  PubMed          Journal:  Actas Urol Esp        ISSN: 0210-4806            Impact factor:   0.994


  15 in total

1.  Predicting biochemical recurrence-free survival for patients with positive pelvic lymph nodes at radical prostatectomy.

Authors:  Christian von Bodman; Guilherme Godoy; Daher C Chade; Angel Cronin; Laura J Tafe; Samson W Fine; Vincent Laudone; Peter T Scardino; James A Eastham
Journal:  J Urol       Date:  2010-05-15       Impact factor: 7.450

2.  Predicting 15-year prostate cancer specific mortality after radical prostatectomy.

Authors:  Scott E Eggener; Peter T Scardino; Patrick C Walsh; Misop Han; Alan W Partin; Bruce J Trock; Zhaoyong Feng; David P Wood; James A Eastham; Ofer Yossepowitch; Danny M Rabah; Michael W Kattan; Changhong Yu; Eric A Klein; Andrew J Stephenson
Journal:  J Urol       Date:  2011-01-15       Impact factor: 7.450

3.  Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration.

Authors:  Daher C Chade; Shahrokh F Shariat; Angel M Cronin; Caroline J Savage; R Jeffrey Karnes; Michael L Blute; Alberto Briganti; Francesco Montorsi; Henk G van der Poel; Hendrik Van Poppel; Steven Joniau; Guilherme Godoy; Antonio Hurtado-Coll; Martin E Gleave; Marcos Dall'Oglio; Miguel Srougi; Peter T Scardino; James A Eastham
Journal:  Eur Urol       Date:  2011-03-21       Impact factor: 20.096

4.  Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis.

Authors:  W U Shipley; H D Thames; H M Sandler; G E Hanks; A L Zietman; C A Perez; D A Kuban; S L Hancock; C D Smith
Journal:  JAMA       Date:  1999-05-05       Impact factor: 56.272

5.  Time trends and local variation in primary treatment of localized prostate cancer.

Authors:  Matthew R Cooperberg; Jeanette M Broering; Peter R Carroll
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

6.  Standard versus limited pelvic lymph node dissection for prostate cancer in patients with a predicted probability of nodal metastasis greater than 1%.

Authors:  Karim Touijer; Farhang Rabbani; Javier Romero Otero; Fernando P Secin; James A Eastham; Peter T Scardino; Bertrand Guillonneau
Journal:  J Urol       Date:  2007-05-11       Impact factor: 7.450

7.  Radical prostatectomy for stage D1 prostate cancer. Prognostic variables and results of treatment.

Authors:  M Golimbu; J Provet; S Al-Askari; P Morales
Journal:  Urology       Date:  1987-11       Impact factor: 2.649

8.  Cancer statistics, 2013.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2013-01-17       Impact factor: 508.702

9.  Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy.

Authors:  Martin C Schumacher; Fiona C Burkhard; George N Thalmann; Achim Fleischmann; Urs E Studer
Journal:  Eur Urol       Date:  2008-05-21       Impact factor: 20.096

10.  Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy.

Authors:  Alberto Briganti; Jeffrey R Karnes; Luigi Filippo Da Pozzo; Cesare Cozzarini; Andrea Gallina; Nazareno Suardi; Marco Bianchi; Massimo Freschi; Claudio Doglioni; Ferruccio Fazio; Patrizio Rigatti; Francesco Montorsi; Michael L Blute
Journal:  Eur Urol       Date:  2008-10-01       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.